Evaluating How Apixaban Affects Blood Clotting in Adults with New Multiple Myeloma Compared to Adults Having Total Knee Replacement Surgery

What this Trial Is About

Researchers are investigating how Apixaban, a medication recommended to prevent blood clots, affects blood clotting in patients with newly diagnosed multiple myeloma MM compared to patients undergoing total knee replacement surgery who also receive blood clot prevention. This study aims to understand if differences in how the drug is processed in the body impact its ability to reduce blood clotting in these two groups. The findings may help improve blood clot prevention in MM patients. The study includes two groups one with patients newly diagnosed with multiple myeloma who need Apixaban to prevent blood clots, and another with patients having surgery for total knee replacement who also require Apixaban. Blood samples will be taken from both groups to measure the medications concentration and its effects on blood clotting over a 12-hour period after treatment. Participants will have blood samples collected to analyze how Apixaban influences thrombin generation, a key factor in blood clotting, measured 2 hours after treatment and monitored over 12 hours. The study will track Apixaban levels and several clotting parameters, including lag time, time to peak, and thrombin peak. This non-randomized, single-blind trial will last until September 2027, and participants safety and clotting responses will be carefully observed throughout.

Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma